Targeting KIF20A to treat glioblastoma
Official title: Investigating KIF20A as a therapeutic target in glioblastoma
Funded at Ohio State University · NIH-10947506 · Data updated 2026-11-12
This study is looking at a protein called KIF20A to see if blocking it can help kill glioblastoma cells, which could lead to new treatment options for patients with this tough brain tumor.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $404,974 |
| NIH project number | 1R21CA271217-01A1 |
| Project ID | NIH-10947506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those with IDH-wild-type tumors.
✕Less likely to help
Patients with other types of brain tumors or those who do not have glioblastoma may not benefit from this research.
What this research studies
This research investigates the role of KIF20A, a protein involved in cell division, as a potential therapeutic target for glioblastoma, an aggressive brain tumor. The study aims to explore how inhibiting KIF20A can lead to the death of cancer cells, particularly using small molecules and CRISPR technology. By understanding the effects of KIF20A on cell viability and mitotic processes, the research seeks to develop new treatment strategies that could overcome the limitations of current therapies. Patients with glioblastoma may benefit from this innovative approach that targets a specific vulnerability in their cancer cells.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Summers, Matthew K — Ohio State University
- Study coordinator: Summers, Matthew K
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.